The paradigm of precision medicine implies that breast cancer treatment should be tailored based on inherent risk of recurrence and/or individual sensitivity to various chemotherapies. A recent trial of olaparib in women with a BRCA1/2 mutation provides supporting evidence for this paradigm and suggests that the identification of genetic variants at the time of diagnosis might benefit an increasing number of patients.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants
npj Breast Cancer Open Access 12 May 2023
-
Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception
Breast Cancer Research and Treatment Open Access 01 March 2023
-
Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing
British Journal of Cancer Open Access 17 June 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dorling, L. et al. Breast cancer risk genes - association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428–439 (2021).
Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 (2017).
Tutt, A. N. J. et al. Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394–2405 (2021).
Narod, S. A. et al. Predictors of survival for breast cancer patients with a BRCA1 mutation. Breast Cancer Res. Treat. Apr. 168, 513–521 (2018).
Jonasson, J. G. et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br. J. Cancer. 115, 776–783 (2016).
Evans, D. G. et al. Survival from breast cancer in women with a BRCA2 mutation by treatment. Br. J. Cancer. 124, 1524–1532 (2021).
Narod, S. A. et al. Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res. Treat. 138, 273–279 (2013).
Cybulski, C. et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 16, 638–644 (2015).
Metcalfe, K. et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 348, g226 (2014).
Metcalfe, K. et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 1, 306–313 (2015).
Metcalfe, K. A. et al. Rapid genetic testing for BRCA1 and BRCA2 mutations at the time of breast cancer diagnosis: an observational study. Ann. Surg. Oncol. 28, 2219–2226 (2021).
Acknowledgements
The author is the recipient of a Tier I Canada Research Chair and is supported and receives funding through the Peter Gilgan Centre for Women’s Cancers.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Narod, S.A. Adjuvant olaparib — should all patients with breast cancer have genetic testing?. Nat Rev Clin Oncol 18, 607–608 (2021). https://doi.org/10.1038/s41571-021-00544-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00544-7
This article is cited by
-
Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception
Breast Cancer Research and Treatment (2023)
-
PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants
npj Breast Cancer (2023)
-
Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing
British Journal of Cancer (2022)